Retatrutide, being studied by Eli Lilly, is a “triple G” agonist—a single molecule that targets three distinct metabolic hormone receptors:
- GLP-1 (Glucagon-like peptide-1) – suppresses appetite and delays gastric emptying.
- GIP (Glucose-dependent insulinotropic polypeptide) – enhances insulin response and improves lipid storage.
- Glucagon – stimulates direct hepatic fat oxidation (fat burning) and increases overall energy expenditure.
While single (e.g., semaglutide) and dual (e.g., tirzepatide) receptor agonists significantly reduce weight and body fat, the addition of the glucagon receptor mechanism specifically targets and clears intrahepatic (liver) fat in ways previously unseen with single or dual incretin therapies.
Key Clinical Findings in Liver Disease
Retatrutide has been primarily studied for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatohepatitis (MASH/NASH).
1. Near-Total Elimination of Liver Fat (Phase 2 Data)
In a landmark Phase 2 substudy led by Dr. Arun Sanyal (published in Nature Medicine) involving patients with obesity and MASLD, retatrutide demonstrated unprecedented efficacy in clearing liver fat measured via magnetic resonance imaging proton density fat fraction (MRI-PDFF):
- Dose-Dependent Fat Reduction at 24 Weeks:
- 1 mg: $-42.9\%$
- 4 mg: $-57.0\%$
- 8 mg: $-81.4\%$
- 12 mg: $-82.4\%$
- Placebo: $+0.3\%$
- 48-Week Outcomes:
- At the higher doses (8 mg and 12 mg), average liver fat content dropped by 81.7% to 86.0%.
- Normalization Rate: Over 89% to 93% of participants on higher doses achieved complete normalization of liver fat levels (defined as $<5\%$ liver fat content).
2. Resolution of Inflammation & Biomarkers of Fibrosis
Beyond fat reduction (steatosis), researchers tracked biomarkers of active liver injury and early fibrosis:
- Significant drops in circulating ALT (alanine aminotransferase) and AST (aspartate aminotransferase) enzymes.
- Favorable shifts in blood-based markers of liver inflammation and scarring (fibrosis), signaling that lowering liver fat quickly halts ongoing cellular damage in hepatocytes.
3. Mechanistic Advantage: Glucagon Receptor Agonism
Clinical investigators emphasize that retatrutide’s efficacy in liver disease stems directly from its glucagon component. Glucagon signaling increases mitochondrial fatty acid oxidation inside liver cells, effectively forcing the liver to burn through stored fat deposits directly, rather than relying solely on systemic weight loss to drain hepatic fat stores over time.
Phase 3 Studies & Current Status
Building on Phase 2 findings, Eli Lilly incorporated MASLD and MASH/NASH outcomes into its broader clinical trial architecture:
- SYNERGY-OUTCOMES & Phase 3 Trials: Ongoing late-stage studies are evaluating long-term outcomes to verify whether retatrutide prevents progression to cirrhosis, major liver events, or long-term cardiovascular complications.
- Head-to-Head Comparisons: Trials comparing retatrutide directly against dual-agonist therapies (such as tirzepatide) are tracking comparative hepatic fat reduction and tolerability.